The Food and Drug Administration has contracted with real-world evidence company Aetion to use their platform for the assessment of COVID-19 inpatient medical products. The Aetion Evidence Platform®, which analyzes real-world data (RWD) pulled from electronic health records and medical claims, will enable the FDA to assess inpatient COVID-19 treatments in real time.
Read More
Read More